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Introduction: Circulating CD4 T cells expressing CXCR5, ICOS and/or PD-1 are counterparts of follicular helper
T cells (Tfh). There are three subpopulations of circulating Tfh (cTfh): CXCR5 + CXCR3 + CCR6- (Tfh-Th1), CXCR5 +
CXCR3-CCR6- (Tfh-Th2) and CXCR5 + CXCR3-CCR6+ (Tfh-Th17). Our objective was to study the B cell helping
capacity of cTfh subsets, and examine their frequency in Rheumatoid Arthritis (RA) patients, together with the
frequency of circulating plasmablasts (CD19 + CD20-CD38high).
Methods: Peripheral blood was drawn from RA patients with active disease (RA-a, DAS28 >2.6) (n = 17), RA in
remission (RA-r, DAS28 <2.6) (n = 17) and healthy controls (HC) (n = 34). cTfh and plasmablast frequencies were
determined by flow cytometry. Cocultures of sorted CD4 + CXCR5+ T cell subpopulations were established with
autologous CD19 + CD27- naïve B cells of HC, and concentrations of IgG, A and M were measured in supernatants.
Results: Isolated Tfh-Th2 and Tfh-Th17 but not Tfh-Th1 cells, induced naïve B cells to secrete IgG and IgA. The
frequency of CXCR5+ cells gated for CD4+ T cells was not different among HC, RA-a and RA-r. In contrast, both
RA-a and RA-r patients demonstrated an increased frequency of CD4 + CXCR5 + ICOS+ T cells and augmented
(%Tfh-Th2 + %Tfh-Th17)/%Tfh-Th1 ratio as compared with HC. In addition, RA-a but not RA-r patients, showed an
increased frequency of circulating plasmablasts.
Conclusion: Both RA-a and RA-r patients demonstrate an increased frequency of cTfh and overrepresentation of
cTfh subsets bearing a B cell helper phenotype, suggesting that altered germinal center dynamics play a role in RA
pathogenesis. In contrast, only RA-a patients show an increased proportion of circulating plasmablasts.Introduction
Rheumatoid Arthritis (RA) is a systemic autoimmune con-
dition characterized by chronic joint inflammation. B cells
actively participate in its pathogenesis not only through
the production of high-affinity and class-switched auto-
antibodies [1-3]: alterations in the capacity of B cells to
present antigen, secrete cytokines, and modulate T cell
function, are also implicated in RA [1].
Follicular helper T cells (Tfh), a major subset of effector
T cells, promote B cell maturation and antibody production* Correspondence: mariaeugenia.miranda@salud.madrid.org
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unless otherwise stated.[4-9]. They are characterized by the expression of the tran-
scription factor BCL-6, by their surface phenotype (CD4 +
CXCR5 + ICOS + PD-1+) and their cytokine profile (IL-21,
IL-10, IL-17) [4-10]. Tfh cells play an important role in the
pathogenesis of autoimmunity [11], and increased numbers
have been described in murine models of systemic lupus
erythematosus (SLE) [11-13] and inflammatory arthritis
[14]; in fact, strategies directed at reducing Tfh cell gen-
eration in these animal models seem to ameliorate dis-
ease manifestations [13,15].
Classical Tfh cells are located in secondary lymphoid or-
gans [4-9], which prevents their routine study in human
patients. Several reports have subsequently described cir-
culating populations of CD4 T cells that express CXCR5tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Clinical characteristics of RA-a and RA-r patients
Variable RA-a (n = 17) RA-r (n = 17)
Age, years, median (IQR) 57 (54 to 63.5) 53.5 (44 to 57.5)
Female, n (%) 16 (94) 13 (76.5)
Disease duration, years, median (IQR) 12.5 (6 to 20) 10 (6 to 16.5)
Disease activity in 28 joints (DAS28)
score, median (IQR)
3.4 (3 to 4.4) 2 (1.7 to 2.4)
Rheumatoid factor-positive, n(%) 16 (94) 16 (94)
Anti-citrullinated peptide
antibodies-positive, n (%)
14 (82) 14 (82)
Methotrexate, n (%) 17 (100) 17 (100)
Prednisone ≤5 mg/day, n (%) 11 (65) 4 (24)
Leflunomide, n (%) 2 (12) 3 (18)
Hydroxychloroquine, n (%) 2 (12) 4 (24)
RA-a: RA patients with active disease (DAS28 >2.6); RA-r: RA patients in remission
(DAS28 <2.6) [31].
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true Tfh cells [16-20]. Increased frequencies of circulating
Tfh cell counterparts (cTfh) have been associated with
autoimmune diseases such as SLE [16,20], Sjögren’s Syn-
drome [21], autoimmune thyroiditis [22], chronic active
hepatitis [23] and myasthenia gravis [24]. To date, only a
few articles on cTfh cells in RA have been published and
results are discordant among them [20,25-28].
More recently, phenotypic and functionally distinct
subpopulations of cTfh cells have been described, ac-
cording to the differential expression of the chemoquine
receptors CXCR3 and CCR6 on CD4 + CXCR5+ T cells
[17]. An altered balance of these cTfh subsets is associ-
ated with autoimmunity in children with juvenile derm-
atomyositis [17] and in adult patients with SLE [29] but
to our knowledge has not been investigated in RA.
Therefore, our objective was to study the frequency of
cTfh and cTfh cell subsets together with the frequency of
circulating plasmablasts (CD19 + CD20-CD38high B cells),
in patients with RA. We observed that both RA patients
with active disease and RA patients with inactive disease
demonstrate an increased frequency of cTfh (CD3 +CD4 +
CXCR5 + ICOS+) together with an overrepresentation
of cTfh subsets bearing a phenotype associated with B cell
helping capacity (CD3 +CD4 +CXCR5+ CCR6 + CXCR3-
and CD3 +CD4 + CXCR5 + CCR6-CXCR3-). In contrast,
only RA patients with active disease show an increased
proportion of circulating plasmablasts.
Methods
Ethics statement
The study was approved by the Hospital La Paz - IdiPAZ
Ethics Committee, and all subjects provided written in-
formed consent according to the Declaration of Helsinki.
Patients
Peripheral blood was obtained from 34 RA patients with
established disease and from 34 age- and sex-matched
healthy controls (HC). RA patients fulfilled at least four
1987 American College of Rheumatology criteria [30], and
were receiving non-biological disease-modifying anti-
rheumatic drugs (DMARDs) with or without low-dose
prednisone. Among RA patients, 17 were in remission as
defined by a disease activity in 28 joints (DAS28) score
<2.6 (RA-r) and 17 had active disease defined by a DAS28
score >2.6 (RA-a) [31]. All patients tested positive for ei-
ther rheumatoid factor (RF) or anti-citrullinated peptide
antibodies (ACPA), and all of them were receiving metho-
trexate. Clinical data are summarized in Table 1.
Isolation of CD4+ T cells and B cells from human
peripheral blood
Peripheral blood mononuclear cells (PBMCs) were sepa-
rated immediately after blood sample collection, by Ficoll-Hypaque (GE Healthcare Biosciences AB, Uppsala, Sweden)
density gradient centrifugation. CD4+ T or B cells were
purifed from freshly isolated PBMCs by exhaustive immu-
nomagnetic negative selection in an Automacs (Miltenyi
Biotec, Bergisch Gladbach, Germany), using the CD4+ T
Cell Isolation Kit or the B Cell Isolation Kit II from
Miltenyi Biotec. Isolated CD4+ T cells or CD19+ B
cells were >98% pure. CD4 + CXCR5+ were selected
from total CD4+ T cells using PE-labeled CXCR5
microbeads (Miltenyi Biotec). Subsequently, cTfh sub-
populations were sorted from CD4 + CXCR5+ T cells
in a FACSVantage SE flow cytometer (BD Biosciences,
San Jose, CA, USA) after staining isolated CD4 +
CXCR5+ T cells with CXCR3 and CCR6. Sorting was
directed to isolating CXCR5 + CXCR3 + CCR6- T cells
(Tfh-Th1 cells), CXCR5 +CXCR3-CCR6- T cells (Tfh-Th2
cells) and CXCR5+ CXCR3-CCR6+ Tcells (Tfh-Th17 cells).
Naïve (CD19 + CD27-) B cells were selected from total
CD19+ B cells by negative selection using CD27+
microbeads (Miltenyi Biotec). T and B cell subpopulations
were >98% pure and used immediately after isolation.
B cell/ T cell co-cultures
To assess the functional capacity of cTfh subpopulations,
sorted peripheral blood Tfh-Th1, Tfh-Th2 or Tfh-Th17
cells (5 × 104 cells/well), were co-cultured for 13 days with
autologous naïve B (CD19 + CD27-) cells (5 × 104 cells/
well) in U-bottom 96-well plates containing RPMI 1640
medium (Lonza, Alendale, NJ, USA) with 10% FCS,
2 mM L-glutamine, 50 U/ml penicillin, 50 μg/ml strepto-
mycin and 50 μM 2-mercapto-ethanol (complete RPMI
medium). Endotoxin-reduced staphylococcal enterotoxin
B (SEB) (1 μg/ml) (Sigma-Aldrich, St Louis, MO, USA)
was also added to the cultures, as the Ig production in
Tfh/B cell cocultures has been shown to depend on cog-
nate T/B cell interactions [16]. Concentrations of IgG,
Figure 1 Functional capacity of circulating CD4 + CXCR5+ T cell
subsets. CD4 + CXCR5+ T cell subsets (Tfh-Th1, Tfh-Th2 or Tfh-Th17)
isolated from peripheral blood of HC were co-cultured with autologous
CD19 + CD27- naïve B cells for 13 days. Shown are concentrations of
IgG, IgA and IgM in 13-day co-culture supernatants. Line and bar
graphs represent the mean and SD of five independent experiments.
Tfh-Th1 cells, CXCR5 + CXCR3 + CCR6- T cells; Tfh-Th17 cells, CXCR5+
CXCR3-CCR6+ T cells; Tfh-Th2 cells, CXCR5 + CXCR3-CCR6- T cells.
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by ELISA.
Flow cytometry
The frequency and phenotype of Tfh-like cells and plas-
mablasts present in the peripheral blood of RA patients
and HC was assessed by flow cytometry in a FACSCali-
bur flow cytometer using CellQuest software (BD Biosci-
ences), after staining freshly isolated PBMCs with
antibodies directed against surface phenotypic markers.
Fluorochrome-conjugated mAbs from BD Pharmingen
(San Diego, CA, USA) were used to examine the expres-
sion of CD3, CD4, CD8, CXCR5, ICOS, PD-1, CCR6,
CXCR3, CD19, CD20, and CD38.
ELISA
Cell-free co-culture supernatants were collected and
stored at −80°C. The concentrations of immunoglobulins
were measured by ELISA. In brief, 96-well plates
(MaxiSorp, Thermo Fisher Scientific, Waltham, MA,
USA) were coated overnight at 4°C with 10 μg/ml
mouse monoclonal anti-human IgG, IgA or IgM (AbD
Serotec, Munich, Germany), and subsequently blocked
with 2% BSA/PBS. Standard curves of human IgG, IgA
or IgM (Sigma-Aldrich) together with culture superna-
tants diluted in 2% BSA/PBS were incubated for
3 hours at room temperature, washed and developed
with horseradish peroxidase-conjugated goat anti-human
IgG, IgA or IgM (AbD serotec) followed by TMB substrate
solution (Pierce Biotechnology, Rockford, IL, USA). Ab-
sorbance was measured at 450 nm in a Synergy H4 Hybrid
Multi-Mode Microplate Reader (BioTec Instruments, Inc.,
Winoosi, VT, USA).
Statistical analysis
Comparison between groups was by Mann-Whitney or
Kruskal-Wallis test. When appropriate, Bonferroni cor-
rection for multiple comparisons was applied. Correla-
tions were analyzed using Spearman’s rank correlation
coefficient. All analyses were performed using Prism
version 5.0 software (GraphPad Software, San Diego,
CA, USA).
Results
Functional capacity of cTfh subpopulations
Our first goal was to examine the functional capacity of
sorted peripheral blood Tfh-Th1, Tfh-Th2 and Tfh-Th17
cells. In co-cultures with autologous Tfh-Th2 or Tfh-
Th17 cells, naïve B cells secreted both IgG and IgA, to-
gether with IgM (Figure 1). In contrast, naïve B cells
co-cultured with Tfh-Th1 cells did not produce detect-
able IgG or IgA but only low amounts of IgM (Figure 1).
This indicates that among circulating CXCR5+ T cells,
only Tfh-Th2 and Tfh-Th17, but not Tfh-Th1 cells, areable to induce maturation of naïve B cells, which is con-
sistent with results published by Morita et al. [17].An increased frequency of circulating Tfh counterparts is
apparent in the peripheral blood of RA patients with
active or inactive disease
We then sought to examine the expression of Tfh pheno-
typic surface markers on CD4+ T cells present in the per-
ipheral blood of RA-a or RA-r patients. Importantly, the
absolute numbers of circulating CD4+ T cells were not
different among the three studied groups (mean ± stand-
ard error of the mean (SEM), 1,141.0 ± 142.8 × 103 CD4+
T cells/ml in RA-a versus 950.6 ± 132.3 in RA-r, versus
1,024.2 ± 163.8 in HC, P >0.1). In addition, the frequency
of CXCR5+ cells among circulating CD4 + T lymphocytes
was not different in RA-a or RA-r patients as compared
with HC (Figure 2A). In contrast, the frequencies of circu-
lating CD4 +CXCR5 + ICOS+ T cells, which are consid-
ered as circulating counterparts of classical Tfh cells
[16,18,19], were significantly increased both in RA-a and
RA-r patients (Figure 2B). Among RA patients, there was
no correlation between disease activity parameters and
frequency of cTfh (Figure 2C).RA patients with active or inactive disease demonstrate
an altered balance of cTfh subsets
RA patients with active or inactive disease demonstrated a
decreased frequency of circulating Tfh-Th1 cells together
with an increased frequency of Tfh-Th17 cells, whereas
the frequency of Tfh-Th2 cells tended to be elevated
but was not statistically different from HC (Figure 3A).
Furthermore, the sum of %Tfh-Th2 plus %Tfh-Th17 cells,
and the ratio (%Tfh-Th2 +%Tfh-Th17)/%Tfh-Th1 were
Figure 2 Frequency of circulating follicular helper T cells (cTfh) in patients with rheumatoid arthritis (RA). (A) The frequency of
circulating CD4 + CXCR5+ T cells was not different in RA patients with active (RA-a) or inactive disease (RA-r) as compared with controls (HC).
Histograms represent CXCR5 expression in cells gated for CD3 and CD4. (B) Increased frequency of circulating Tfh counterparts in RA-a or RA-r
patients, defined as CD4 + CXCR5 + ICOS+ T cells. Representative dot plots demonstrate ICOS and CXCR5 expression in cells gated for CD3 and
CD4. (C) Relationship between cTfh proportions and disease activity as determined by disease activity in 28 joints (DAS28) score [31]. In A and B,
box and whiskers plots represent the median, interquartile range, maximum and minimum values calculated from the 17 RA-a patients, 17 RA-r
patients and 34 HC that were studied. *P <0.01 versus HC.
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with HC (Figure 3B).
That is, both RA-a and RA-r patients demonstrated a
relative overabundance of Tfh cell subsets bearing a B
cell helper phenotype. Among RA patients, there was no
correlation between disease activity parameters and the
observed proportions of cTfh subset or cTfh subset ra-
tios (Figure 3C).
RA patients with active disease demonstrate an increased
frequency of circulating plasmablasts
The absolute number of circulating CD19+ cells was not
different in RA patients with active or inactive disease as
compared with controls (mean ± SEM, 86.65 ± 13.06 ×
103 CD19+ cells/ml in RA-a versus 87.51 ± 15.78 in RA-
r patients versus 86.70 ± 9.49 in HC). At the same time,
the frequency of circulating plasmablasts, defined as
CD19 + CD20-CD38high B cells, was increased in RA-a
but not in RA-r patients (Figure 4A). Interestingly, in
RA patients, the frequency of circulating plasmablasts
was positively correlated not only with the frequency
of circulating Tfh counterparts but also with the ratio(%Tfh-Th2 + %Tfh-Th17)/%Tfh-Th1 cells, (Figure 4B).
Among RA patients, there was no correlation between
disease activity parameters and proportions of circulat-
ing plasmablasts (Figure 4C).
Discussion
The association of RA with high-affinity, class-switched
autoantibodies [1-3], indicates the implication of B helper
T cells in disease pathogenesis and therefore we deemed it
interesting to study cTfh biology in this condition.
It is herein described that among circulating CD4 +
CXCR5+ T cells, only sorted Tfh-Th2 and Tfh-Th17 but
not Tfh-Th1 cells, display functional properties of clas-
sical Tfh present in the germinal centers of secondary
lymphoid organs: Tfh-Th2 and Tfh-Th17 but not Tfh-
Th1 cells, had the capacity to promote maturation and
induce isotype switching of naïve B cells, as previoulsy
reported by Morita et al. [17]. In addition, we observed
that not only RA patients with active disease but also
RA patients in remission, demonstrate an increased
frequency of cTfh defined as CD4 + CXCR5 + ICOS+
T cells [16,18,19], together with an overrepresentation of
Figure 3 Frequency of circulating follicular helper T cell (cTfh) subsets in patients with rheumatoid arthritis (RA). (A) Frequency of
circulating Tfh-Th1, Tfh-Th2 and Tfh-Th17 cells in R-a, RA-r and HC. Representative dot plots demonstrate CXCR3 and CCR6 expression in cells
gated for CD3, CD4 and CXCR5. (B). Overabundance of Tfh-Th2 and Tfh-Th17 cells over Tfh-Th1 cells in RA-a and RA-r patients. (C) Relation of cTfh
subset proportions or ratio with disease activity as determined by disease activity in 28 joints (DAS28) score [31]. *P <0.01 versus HC. Tfh, Follicular
helper T cells; Tfh-Th1 cells, CXCR5 + CXCR3 + CCR6- T cells; Tfh-Th17 cells, CXCR5+ CXCR3-CCR6+ T cells; Tfh-Th2 cells, CXCR5 + CXCR3-CCR6- T cells.
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and Tfh-Th17). The augmented CD4 + CXCR5 + ICOS+
T cell proportions are not attributable to the presence of
activated T cells in peripheral blood; although CXCR5 is
typically upregulated upon in vivo T cell activation [32],total CD4 + CXCR5+ T cells themselves were not in-
creased in our RA patients with active or inactive disease.
Therefore, this constitutive overabundance of cTfh in
RA seems related to disease phenotype and pathogenic
mechanisms but not to RA disease activity, as has been
Figure 4 An increased frequency of circulating plasmablasts in rheumatoid arthritis patients with active disease (RA-a) is correlated
with the frequency of circulating follicular helper T cells (cTfh). (A) Patients RA-a but not with rheumatoid arthritis in remission (RA-r)
demonstrate an increased frequency of circulating plasmablasts. Shown are representative dot plots of CD20 and CD38 expression on cells
gated for CD19 (left panel), together with box and whisker plots representing the median, interquartile range, maximum and minimum values
calculated from 17 RA-a patients, 17 RA-r patients and 34 healthy controls (HC) (right panel). *P <0.01 versus HC. (B) The frequency of circulating
plasmablasts in RA-a patients is positively correlated with the frequency of circulating Tfh counterparts and with the ratio (%Tfh-Th2 +%Tfh-Th17)/%
Tfh-Th1 cells. (C) Relation of circulating plasmablast frequencies with disease activity as determined by disease activity in 28 joints (DAS28) score [31].
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scribed an expansion of cTfh in a subset of SLE patients
with severe disease, which does not vary with time, mod-
ifications in disease activity or treatment [16]. In this
context, it has been proposed that increased numbers of
cTfh can be a signature of human immune-mediated dis-
eases [19]. In fact, a causal relation between accumulation of
Tfh cells and autoimmunity has been demonstrated in mice
homozygous for the san allele of Roquin (Roquinsan/san), a
protein regulator of mRNA stability [33]. Roquin represses
ICOS mRNA post-transcriptionally, and homozygosity for
its san allele mediates ICOS overexpression and generation
of Tfh cells [13,33]. Roquinsan/san mice demonstrate in-
creased numbers of Tfh cells together with aberrant GC
formation and positive selection of pathogenic high-
affinity autoantibodies, resulting in a lupus-like phenotype
[13,33]. Furthermore, abrogating Tfh cell generation pre-
vents lupus development in the Roquinsan/san mice, and
transfer of Tfh cells from these mice induces the spontan-
eous formation of GCs [13].
Conversely, patients with loss-of-function mutations in
CD40L, NEMO, STAT3, IL-21R or BTK and patients
with gain-of-function mutations in STAT1, demonstrate
a severely impaired generation of germinal centers to-
gether with decreased circulating CD4 + CXCR5+ T cells
[34], reinforcing the notion that cTfh numbers are a re-
flection of the pool of classical Tfh in lymphoid organs.
The recent description by Morita et al. of three differ-
ent subsets of circulating CD4 + CXCR5+ T cells with
distinct functional properties [17] sheds new light intothe biology of Tfh and their pathogenic implication in
autoimmune conditions. Of note, it has been reported
that among circulating Tfh cells, the Tfh-Th17 subset is
most significantly reduced in all immune deficiencies
above mentioned [34], indicating the importance of
these cells as B cell helpers. In this context, Tfh-Th17
was the most significantly elevated Tfh subset in our RA
patients, which further suggests their leading role in pro-
moting autoantibody production.
Of note, altered proportions of circulating Tfh subsets
in patients with juvenile dermatomyositis (JDM) seem to
be associated with disease activity [17], which contrasts
with findings in our RA patients. This suggests that the
mechanisms leading to an altered regulation of Tfh cell
subset differentiation may be different in JDM and RA.
Interestingly, we observed that whereas RA-a patients
show an increased frequency of circulating plasmablasts,
the frequency of circulating plasmablasts in RA-r was
not different from controls. This parallels reported ob-
servations indicating that response to treatment in RA is
associated with a reduction in the titers of RF and/or
ACPA, whereas RA patients who do not respond to
treatment maintain antibody levels comparable to those
found at baseline [35,36]. Of note, despite a signficant
reduction of RF and/or ACPA levels associated with
therapeutic response, seropositive RA patients rarely be-
come seronegative, indicating the persistence of a consti-
tutive autoimmune alteration [35,36].
A reason for the finding of normal circulating plasma-
blasts in the presence of elevated cTfh proportions in
Arroyo-Villa et al. Arthritis Research & Therapy 2014, 16:500 Page 7 of 8
http://arthritis-research.com/content/16/6/500RA-r patients is not readily apparent to us. We can only
speculate that, in patients who respond and achieve
remission, treatment with non-biological DMARDs may
block the action of constitutively increased Tfh cell
numbers on B cell biology, thereby preventing the gener-
ation of increased proportions of plasmablasts. Con-
versely, in RA patients who do not achieve a complete
response to DMARDs, these drugs would not be able to
modify the function of Tfh. Alternatively, plasmablast
generation through the extrafollicular pathway could
account for the discordance between cTfh and plasma-
blast numbers in patients with active or inactive disease
[37,38].Conclusions
In summary, we have described a constitutively in-
creased frequency of cTfh together with an overrepre-
sentation cTfh subsets bearing a B cell helper phenotype
in RA. This indicates that excessive Tfh cell generation
and altered germinal center dynamics may play a role in
the pathogenesis of this condition. In addition, it points
to modifications of Tfh effector molecules or Tfh subset
balance as future therapeutic targets in RA.
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